Objective:

To explore the impact of geopolitical instability, particularly the Iran conflict, on pharmaceutical supply chains and the preparedness of life sciences companies.

Approach:

• Research Findings: The Operations Outlook 2026 report by Argon & Co highlights that only 22% of firms are preparing for supply chain disruptions despite significant pressures.
• Discussion with Expert: Michel Savini discusses the need for scenario planning and strategic supply chain design to enhance resilience.

Key Findings:

• 62% of life sciences leaders feel pressure to reduce operational costs.
• 40% cite rising raw material costs as their biggest supply chain challenge.
• Medicines requiring refrigeration, such as biologics and vaccines, are particularly vulnerable to geopolitical disruptions.

Interpretation:

Pharmaceutical companies are currently prioritizing immediate cost reductions over long-term resilience strategies, which may leave them exposed to future disruptions.

Limitations:

• Many companies implemented temporary fixes rather than long-term solutions.
• Systematic scenario planning is not widely adopted.

Conclusion:

The ongoing geopolitical instability necessitates a reevaluation of supply chain strategies to ensure the availability of critical medicines.

Sources:

• Argon & Co